Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share
Shares of Torrent Pharmaceuticals rose up to 2.43 per cent to hit an intraday high of Rs 3,180.05 a piece on the BSE
Torrent Group was actively pursuing the acquisition of Cipla and JB Chemicals and Pharmaceuticals but ultimately withdrew due to high valuations demanded by the sellers
Torrent Investments, a promoter entity of Torrent Pharmaceuticals, on Wednesday trimmed a 2.9 per cent stake in the company for Rs 3,086 crore through open market transactions. According to the bulk deal data available with the BSE, Torrent Investments Pvt Ltd sold a total of 99.44 lakh shares or 2.94 per cent stake in Torrent Pharmaceuticals. The shares were sold in the price range of Rs 3,103.07-3,104.40 apiece, taking the combined transaction value to Rs 3,086.37 crore. After the stake sale, the combined holding of promoters of Torrent Pharmaceuticals has come down to 68.31 per cent from 71.25 per cent. Details of the buyers of Torrent Pharmaceuticals' shares could not be ascertained on the BSE. Last week, Torrent Pharmaceuticals reported its consolidated profit after tax rose 17 per cent to Rs 453 crore in the September quarter, led by robust sales in the domestic market. The drug firm had reported a profit after tax (PAT) of Rs 386 crore in the July-September period of the l
At 09:15 am; as many as 10.13 million equity shares representing 3 per cent of total equity of Torrent Pharma have changed hands on the BSE, the exchange data shows.
At an operational level, Torrent Pharma's earnings before interest, tax, depreciation, and amortisation stood at Rs 939 crore, with an Ebitda margin of 32.5 per cent
Divi's Labs share: In the last four days, Divi's Lab share price has surged 13 per cent after global brokerage firm Citi initiated coverage on Divi's Laboratories with a 'Buy' rating
In the past one year, Torrent Pharma has outperformed the market by zooming 94 per cent as compared to 27 per cent rise in the BSE Sensex
Deliberations about the stake purchase are ongoing and no final decisions have been made, the people said. Other bidders may still remain interested in acquiring the stake, the people said
Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.
Revenues in the USA market, however, were down by 12 per cent at Rs 259 crore, falling from Rs 293 crore reported in Q1 FY24
The fall came after the United States Food and Drug Administration (USFDA) issued a Form 483 with five observations for the Indrad unit